Search This Blog

Thursday, May 2, 2019

Thermo Fisher: Blood Biomarker May Flag Patients with Developing Sepsis

Multi-centre analysis shows that incorporation of MR-proADM (mid-regional proadrenomedullin) into an early management of patients with suspected infection protocol may aid rapid clinical decision making in the emergency department
Results from the multi-centre study titled ‘The early identification of disease progression in patients with suspected infection presenting to the emergency department’ have been published in the February issue of Critical Care. In this study, the testing 1175 patients presenting to six European emergency departments (ED) with an initial diagnosis of infection were prospectively enrolled and validated by a secondary analysis of 896 patients with suspected infection from previously published multi-centre study1.
The inappropriate discharge of patients in the early stages of sepsis development is a serious, life-threatening consequence of the complex pathophysiological signs of infection. Indeed, all infections have the potential to manifest into life-threatening conditions, depending on the virulence of the infecting organism and the subsequent pathophysiological host response. Despite a high emphasis being placed on an early identification of patients with sepsis within the ED, failure to identify those with initially low severities, but a high potential for subsequent disease development and progression towards sepsis may lead to either a delayed therapeutic response or inappropriate discharge decisions.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.